The significant effects of NCT-503 combined with perhexiline in vivo, with minimal toxicity and dramatic tumor control, show that PHGDH inhibition combined with mTORC1-signaling inhibition are a promising dual therapy in PHGDH-high cancers. The gene discussed is PHGDH; the disease is neoplasm.